1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
1 of 5
FEATURED COMPANIES
- Abbott Vascular
- AtriCure
- Biosensors International
- BioVentrix
- Bristol-Myers Squibb
- Daiichi Sankyo
- MORE
About Anticoagulant Market
Anticoagulant prevent clot formations or the enlargement of existing clots in the arteries or veins. Heparins, including unfractionated heparin (UFH) and low molecular weight heparin (LMWH); vitamin K antagonists; DTIs; and factor Xa inhibitors are among the anticoagulant that are available in the market. They are used for indications such as heart attack, stroke, deep venous thrombosis (DVT), pulmonary embolism (PE), surgery, angina, dialysis, atrial fibrillation (AF), thrombocytopenia, and myocardial infarction. Bayer HealthCare, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Johnson & Johnson, and Sanofi are some of the top vendors in the market.
The analysts forecast the global anticoagulant market to grow at a CAGR of 7.42% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global anticoagulant market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of branded and generics drugs used to treat coagulation disorders.
The market is divided into the following segments based on geography:
- Americas
- EMEA
- APAC
The report, Global Anticoagulant Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the Key vendors operating in this market.
Key vendors
- Bayer HealthCare
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Daiichi Sankyo
- Johnson & Johnson
- Sanofi
Other prominent vendors
- Abbott Vascular
- Abiomed
- AtriCure
- Biosensors International
- Biotronik
- BioVentrix
- C. R. Bard
Market drivers
- Increasing demand for NOACs
- For a full, detailed list, view the full report
Market challenges
- Increasing cost of NOACs
- For a full, detailed list, view the full report
Market trends
- Strategic alliance
- For a full, detailed list, view the full report
Key questions answered in this report
- What will the market size be in 2021 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?
You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
Anticoagulant prevent clot formations or the enlargement of existing clots in the arteries or veins. Heparins, including unfractionated heparin (UFH) and low molecular weight heparin (LMWH); vitamin K antagonists; DTIs; and factor Xa inhibitors are among the anticoagulant that are available in the market. They are used for indications such as heart attack, stroke, deep venous thrombosis (DVT), pulmonary embolism (PE), surgery, angina, dialysis, atrial fibrillation (AF), thrombocytopenia, and myocardial infarction. Bayer HealthCare, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Johnson & Johnson, and Sanofi are some of the top vendors in the market.
The analysts forecast the global anticoagulant market to grow at a CAGR of 7.42% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global anticoagulant market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of branded and generics drugs used to treat coagulation disorders.
The market is divided into the following segments based on geography:
- Americas
- EMEA
- APAC
The report, Global Anticoagulant Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the Key vendors operating in this market.
Key vendors
- Bayer HealthCare
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Daiichi Sankyo
- Johnson & Johnson
- Sanofi
Other prominent vendors
- Abbott Vascular
- Abiomed
- AtriCure
- Biosensors International
- Biotronik
- BioVentrix
- C. R. Bard
Market drivers
- Increasing demand for NOACs
- For a full, detailed list, view the full report
Market challenges
- Increasing cost of NOACs
- For a full, detailed list, view the full report
Market trends
- Strategic alliance
- For a full, detailed list, view the full report
Key questions answered in this report
- What will the market size be in 2021 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?
You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
Note: Product cover images may vary from those shown
2 of 5
FEATURED COMPANIES
- Abbott Vascular
- AtriCure
- Biosensors International
- BioVentrix
- Bristol-Myers Squibb
- Daiichi Sankyo
- MORE
PART 01: Executive summary
PART 02: Scope of the report
Market overview
Top-vendor offerings
PART 03: Market research methodology
Research methodology
Economic indicators
PART 04: Introduction
Key market highlights
PART 05: Disease overview
PART 06: Pipeline analysis
PART 07: Market landscape
Market overview
Five forces analysis
PART 08: Market segmentation by ROA
Oral anticoagulants
Injectable anticoagulants
PART 09: Market segmentation by drug class
Factor Xa inhibitors
DTIs
Heparin
Vitamin K antagonists
PART 10: Market segmentation by application
DVT
PE
AF
Others
PART 11: Geographical segmentation
Global anticoagulant market in Americas
Anticoagulant market in EMEA
Anticoagulant market in APAC
PART 12: Market drivers
Increasing demand for NOACs
Growing prevalence of coagulation disorders
Increase in hip and knee surgeries
PART 13: Impact of drivers
PART 14: Market challenges
Increasing cost of NOACs
Lack of antidotes in the market for NOACs
Patent expiry: a threat to market
PART 15: Impact of drivers and challenges
PART 16: Market trends
Strategic alliance
Increasing focus toward emerging economies
Patient assistance programs
PART 17: Vendor landscape
Competitive scenario
Other prominent vendors
PART 18: Key vendor analysis
Bayer HealthCare
Boehringer Ingelheim
Bristol-Myers Squibb
Daiichi Sankyo
Johnson & Johnson
Sanofi
PART 19: Appendix
List of abbreviations
PART 20: About the Author
List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Process of blood coagulation
Exhibit 03: Mechanism of action (MoA) of anticoagulant
Exhibit 04: Key customer segments of global anticoagulant market
Exhibit 05: Pipeline analysis 2016
Exhibit 06: Key pipeline molecules
Exhibit 07: Global anticoagulant market overview
Exhibit 08: Global anticoagulant market 2016-2021 ($ billions)
Exhibit 09: Five forces analysis
Exhibit 10: Segmentation of anticoagulant market based on ROA
Exhibit 11: Market share of anticoagulant based on ROA 2016
Exhibit 12: Types of heparin
Exhibit 13: Segmentation of anticoagulant market based on drug class
Exhibit 14: Market share of anticoagulant based on drug class 2016
Exhibit 15: Types of factor Xa inhibitors based on MOA
Exhibit 16: Factor Xa inhibitors in global anticoagulant market 2016-2021 ($ billions)
Exhibit 17: Types of DTIs based on MOA
Exhibit 18: DTIs in global anticoagulant market 2016-2021 ($ billions)
Exhibit 19: Global heparin market 2016-2021 ($ billions)
Exhibit 20: Global vitamin K antagonists market in 2016-2021 ($ billions)
Exhibit 21: Market segmentation by application
Exhibit 22: Market segmentation of anticoagulant based on application
Exhibit 23: Anticoagulant market in Americas 2016-2021 ($ billions)
Exhibit 24: Anticoagulant market in EMEA 2016-2021 ($ billions)
Exhibit 25: Anticoagulant market in APAC 2016-2021 ($ billions)
Exhibit 26: Impact of drivers
Exhibit 27: Patents to expire over forecast period
Exhibit 28: Impact of drivers and challenges
Exhibit 29: Competitive structure analysis of global anticoagulant market 2016
Exhibit 30: Competitive analysis of global anticoagulant market
Exhibit 31: Market share analysis 2016
Exhibit 32: Competitive landscape analysis 2016
Exhibit 33: Bayer HealthCare: Key highlights
Exhibit 34: Bayer HealthCare: Strength assessment
Exhibit 35: Bayer HealthCare: Strategy assessment
Exhibit 36: Bayer HealthCare: Opportunity assessment
Exhibit 37: Bayer HealthCare: YoY revenue and growth rate of XARELTO 2013-2015 ($ billions)
Exhibit 38: Boehringer Ingelheim: Key highlights
Exhibit 39: Boehringer Ingelheim: Strength assessment
Exhibit 40: Boehringer Ingelheim: Strategy assessment
Exhibit 41: Boehringer Ingelheim: Opportunity assessment
Exhibit 42: Boehringer Ingelheim: YoY revenue and growth rate of PRADAXA (global) 2013-2015 ($ billions)
Exhibit 43: Bristol-Myers Squibb: Highlights
Exhibit 44: Bristol-Myers Squibb: Strength assessment
Exhibit 45: Bristol-Myers Squibb: Strategy assessment
Exhibit 46: Bristol-Myers Squibb: Opportunity assessment
Exhibit 47: Bristol-Myers Squibb: YoY revenue and growth rate of ELIQUIS (global) 2013-2015 ($ millions)
Exhibit 48: Bristol-Myers Squibb: Geographic segmentation of ELIQUIS 2015
Exhibit 49: Daiichi Sankyo: Key highlights
Exhibit 50: Daiichi Sankyo: Strength assessment
Exhibit 51: Daiichi Sankyo: Strategy assessment
Exhibit 52: Daiichi Sankyo: Opportunity assessment
Exhibit 53: Johnson & Johnson: Strength assessment
Exhibit 54: Johnson & Johnson: Strategy assessment
Exhibit 55: Johnson & Johnson: Opportunity assessment
Exhibit 56: Sanofi: Key highlights
Exhibit 57: Sanofi: Strength assessment
Exhibit 58: Sanofi: Strategy assessment
Exhibit 59: Sanofi: Opportunity assessment
Exhibit 60: Sanofi: YoY revenue and growth rate of LOVENOX (global) 2013-2015 ($ billions)
Exhibit 61: Sanofi: Geographical segmentation of LOVENOX 2016
PART 02: Scope of the report
Market overview
Top-vendor offerings
PART 03: Market research methodology
Research methodology
Economic indicators
PART 04: Introduction
Key market highlights
PART 05: Disease overview
PART 06: Pipeline analysis
PART 07: Market landscape
Market overview
Five forces analysis
PART 08: Market segmentation by ROA
Oral anticoagulants
Injectable anticoagulants
PART 09: Market segmentation by drug class
Factor Xa inhibitors
DTIs
Heparin
Vitamin K antagonists
PART 10: Market segmentation by application
DVT
PE
AF
Others
PART 11: Geographical segmentation
Global anticoagulant market in Americas
Anticoagulant market in EMEA
Anticoagulant market in APAC
PART 12: Market drivers
Increasing demand for NOACs
Growing prevalence of coagulation disorders
Increase in hip and knee surgeries
PART 13: Impact of drivers
PART 14: Market challenges
Increasing cost of NOACs
Lack of antidotes in the market for NOACs
Patent expiry: a threat to market
PART 15: Impact of drivers and challenges
PART 16: Market trends
Strategic alliance
Increasing focus toward emerging economies
Patient assistance programs
PART 17: Vendor landscape
Competitive scenario
Other prominent vendors
PART 18: Key vendor analysis
Bayer HealthCare
Boehringer Ingelheim
Bristol-Myers Squibb
Daiichi Sankyo
Johnson & Johnson
Sanofi
PART 19: Appendix
List of abbreviations
PART 20: About the Author
List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Process of blood coagulation
Exhibit 03: Mechanism of action (MoA) of anticoagulant
Exhibit 04: Key customer segments of global anticoagulant market
Exhibit 05: Pipeline analysis 2016
Exhibit 06: Key pipeline molecules
Exhibit 07: Global anticoagulant market overview
Exhibit 08: Global anticoagulant market 2016-2021 ($ billions)
Exhibit 09: Five forces analysis
Exhibit 10: Segmentation of anticoagulant market based on ROA
Exhibit 11: Market share of anticoagulant based on ROA 2016
Exhibit 12: Types of heparin
Exhibit 13: Segmentation of anticoagulant market based on drug class
Exhibit 14: Market share of anticoagulant based on drug class 2016
Exhibit 15: Types of factor Xa inhibitors based on MOA
Exhibit 16: Factor Xa inhibitors in global anticoagulant market 2016-2021 ($ billions)
Exhibit 17: Types of DTIs based on MOA
Exhibit 18: DTIs in global anticoagulant market 2016-2021 ($ billions)
Exhibit 19: Global heparin market 2016-2021 ($ billions)
Exhibit 20: Global vitamin K antagonists market in 2016-2021 ($ billions)
Exhibit 21: Market segmentation by application
Exhibit 22: Market segmentation of anticoagulant based on application
Exhibit 23: Anticoagulant market in Americas 2016-2021 ($ billions)
Exhibit 24: Anticoagulant market in EMEA 2016-2021 ($ billions)
Exhibit 25: Anticoagulant market in APAC 2016-2021 ($ billions)
Exhibit 26: Impact of drivers
Exhibit 27: Patents to expire over forecast period
Exhibit 28: Impact of drivers and challenges
Exhibit 29: Competitive structure analysis of global anticoagulant market 2016
Exhibit 30: Competitive analysis of global anticoagulant market
Exhibit 31: Market share analysis 2016
Exhibit 32: Competitive landscape analysis 2016
Exhibit 33: Bayer HealthCare: Key highlights
Exhibit 34: Bayer HealthCare: Strength assessment
Exhibit 35: Bayer HealthCare: Strategy assessment
Exhibit 36: Bayer HealthCare: Opportunity assessment
Exhibit 37: Bayer HealthCare: YoY revenue and growth rate of XARELTO 2013-2015 ($ billions)
Exhibit 38: Boehringer Ingelheim: Key highlights
Exhibit 39: Boehringer Ingelheim: Strength assessment
Exhibit 40: Boehringer Ingelheim: Strategy assessment
Exhibit 41: Boehringer Ingelheim: Opportunity assessment
Exhibit 42: Boehringer Ingelheim: YoY revenue and growth rate of PRADAXA (global) 2013-2015 ($ billions)
Exhibit 43: Bristol-Myers Squibb: Highlights
Exhibit 44: Bristol-Myers Squibb: Strength assessment
Exhibit 45: Bristol-Myers Squibb: Strategy assessment
Exhibit 46: Bristol-Myers Squibb: Opportunity assessment
Exhibit 47: Bristol-Myers Squibb: YoY revenue and growth rate of ELIQUIS (global) 2013-2015 ($ millions)
Exhibit 48: Bristol-Myers Squibb: Geographic segmentation of ELIQUIS 2015
Exhibit 49: Daiichi Sankyo: Key highlights
Exhibit 50: Daiichi Sankyo: Strength assessment
Exhibit 51: Daiichi Sankyo: Strategy assessment
Exhibit 52: Daiichi Sankyo: Opportunity assessment
Exhibit 53: Johnson & Johnson: Strength assessment
Exhibit 54: Johnson & Johnson: Strategy assessment
Exhibit 55: Johnson & Johnson: Opportunity assessment
Exhibit 56: Sanofi: Key highlights
Exhibit 57: Sanofi: Strength assessment
Exhibit 58: Sanofi: Strategy assessment
Exhibit 59: Sanofi: Opportunity assessment
Exhibit 60: Sanofi: YoY revenue and growth rate of LOVENOX (global) 2013-2015 ($ billions)
Exhibit 61: Sanofi: Geographical segmentation of LOVENOX 2016
Note: Product cover images may vary from those shown
3 of 5
FEATURED COMPANIES
- Abbott Vascular
- AtriCure
- Biosensors International
- BioVentrix
- Bristol-Myers Squibb
- Daiichi Sankyo
- MORE
New Report Released: – Global Anticoagulant Market 2017-2021
The author of the report recognizes the following companies as the key players in the Global Anticoagulant Market: Bayer HealthCare, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Johnson & Johnson, and Sanofi.
Other Prominent Vendors in the market are: Abbott Vascular, Abiomed, AtriCure, Biosensors International, Biotronik, BioVentrix, and C. R. Bard.
Commenting on the report, an analyst from the research team said: “One trend in the market is the strategic alliance. Mergers and acquisitions (M&A) lead the industry toward further consolidation, which, in turn, improves the penetration of the related products. Considering such alliances lead to broader geographical footprint and wider customer base, the underlying market witnesses the benefits regarding volume growth.”
According to the report, one driver in the market is the increasing demand for NOACs. The increasing adoption rates of NOACs is driving the market growth. NOACs target either thrombin or factor Xa to prevent and treat thrombosis. They show quick action and do not require continuous monitoring. They also have better safety and efficacy profiles when compared with conventional therapies such as warfarin. Hence, the adoption rate of NOACs has seen an increment in the anticoagulation market. It was observed that 62% of all the anticoagulant prescriptions were for novel oral anticoagulant during 2010-2013.
Further, the report states that one challenge in the market is the increasing cost of NOACs. The cost of NOACs that are available in the market is higher than the conventional drugs such as warfarin. The average cost of generic warfarin for a months' supply is $15.6. However, the average costs for a months' supply of NOACs such as dabigatran 100 mg and 150 mg capsules are $68.95 and $61.52, respectively. Such high cost of NOACs will lower the demand for the drugs and customers are reluctant to accept the drug. It also limits governments from including these drugs in national reimbursement lists as cheaper drugs are available in the market. Thus, the high cost of these drugs limits the growth of the market.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
The author of the report recognizes the following companies as the key players in the Global Anticoagulant Market: Bayer HealthCare, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Johnson & Johnson, and Sanofi.
Other Prominent Vendors in the market are: Abbott Vascular, Abiomed, AtriCure, Biosensors International, Biotronik, BioVentrix, and C. R. Bard.
Commenting on the report, an analyst from the research team said: “One trend in the market is the strategic alliance. Mergers and acquisitions (M&A) lead the industry toward further consolidation, which, in turn, improves the penetration of the related products. Considering such alliances lead to broader geographical footprint and wider customer base, the underlying market witnesses the benefits regarding volume growth.”
According to the report, one driver in the market is the increasing demand for NOACs. The increasing adoption rates of NOACs is driving the market growth. NOACs target either thrombin or factor Xa to prevent and treat thrombosis. They show quick action and do not require continuous monitoring. They also have better safety and efficacy profiles when compared with conventional therapies such as warfarin. Hence, the adoption rate of NOACs has seen an increment in the anticoagulation market. It was observed that 62% of all the anticoagulant prescriptions were for novel oral anticoagulant during 2010-2013.
Further, the report states that one challenge in the market is the increasing cost of NOACs. The cost of NOACs that are available in the market is higher than the conventional drugs such as warfarin. The average cost of generic warfarin for a months' supply is $15.6. However, the average costs for a months' supply of NOACs such as dabigatran 100 mg and 150 mg capsules are $68.95 and $61.52, respectively. Such high cost of NOACs will lower the demand for the drugs and customers are reluctant to accept the drug. It also limits governments from including these drugs in national reimbursement lists as cheaper drugs are available in the market. Thus, the high cost of these drugs limits the growth of the market.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
4 of 5
- Bayer HealthCare
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Daiichi Sankyo
- Johnson & Johnson
- Sanofi
- Abbott Vascular
- Abiomed
- AtriCure
- Biosensors International
- Biotronik
- BioVentrix
- C R Bard
Note: Product cover images may vary from those shown
5 of 5
LOADING...
